Clinical audit of current <i>Helicobacter pylori</i> treatment outcomes in Singapore.

ABSTRACT:

Introduction

H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline). Second-line therapies include 14-day PBMT and PAL (PPI, amoxicillin, levofloxacin). This clinical audit examined current treatment outcomes in Singapore.

Methods

Clinical data of H. pylori-positive patientswho underwent empirical first- and second-line eradication therapies from 1 January 2017 to 31 December 2018 were reviewed. Treatment success was determined by ¹³C urea breath test performed at least 4 weeks after treatment and 2 weeks off PPI.

Results

A total of 963 patients (862 PAC, 36 PMC

SUBMITTER: Ang TL 

PROVIDER: S-EPMC9678135 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature